Published in J Clin Oncol on March 20, 2005
Hematopoietic cell transplantation (HCT)-specific comorbidity index: a new tool for risk assessment before allogeneic HCT. Blood (2005) 10.63
Influence of immunosuppressive treatment on risk of recurrent malignancy after allogeneic hematopoietic cell transplantation. Blood (2011) 1.90
MHC haplotype matching for unrelated hematopoietic cell transplantation. PLoS Med (2007) 1.83
Survival for older patients with acute myeloid leukemia: a population-based study. Haematologica (2012) 1.81
Reduced-intensity conditioning followed by allogeneic hematopoietic cell transplantation for adult patients with myelodysplastic syndrome and myeloproliferative disorders. Biol Blood Marrow Transplant (2008) 1.75
Allogeneic hematopoietic stem cell transplantation for the treatment of high-risk acute myelogenous leukemia and myelodysplastic syndrome using reduced-intensity conditioning with fludarabine and melphalan. Biol Blood Marrow Transplant (2007) 1.74
Development of tumor-reactive T cells after nonmyeloablative allogeneic hematopoietic stem cell transplant for chronic lymphocytic leukemia. Clin Cancer Res (2009) 1.74
NCI First International Workshop on the Biology, Prevention, and Treatment of Relapse after Allogeneic Hematopoietic Stem Cell Transplantation: Report from the Committee on Treatment of Relapse after Allogeneic Hematopoietic Stem Cell Transplantation. Biol Blood Marrow Transplant (2010) 1.72
Outcomes following HSCT using fludarabine, busulfan, and thymoglobulin: a matched comparison to allogeneic transplants conditioned with busulfan and cyclophosphamide. Biol Blood Marrow Transplant (2008) 1.67
Allogeneic haematopoietic stem cell transplantation: individualized stem cell and immune therapy of cancer. Nat Rev Cancer (2010) 1.62
Comorbidities and survival in a large cohort of patients with newly diagnosed myelodysplastic syndromes. Leuk Res (2009) 1.57
NCI First International Workshop on the Biology, Prevention, and Treatment of Relapse after Allogeneic Hematopoietic Stem Cell Transplantation: report from the Committee on the Epidemiology and Natural History of Relapse following Allogeneic Cell Transplantation. Biol Blood Marrow Transplant (2010) 1.56
Graft-versus-host disease and graft-versus-tumor effects after allogeneic hematopoietic cell transplantation. J Clin Oncol (2013) 1.53
Fludarabine and 2-Gy TBI is superior to 2 Gy TBI as conditioning for HLA-matched related hematopoietic cell transplantation: a phase III randomized trial. Biol Blood Marrow Transplant (2013) 1.51
Establishment of a murine graft-versus-myeloma model using allogeneic stem cell transplantation. PLoS One (2014) 1.45
Reduced-intensity allogeneic transplant in patients older than 55 years: unrelated umbilical cord blood is safe and effective for patients without a matched related donor. Biol Blood Marrow Transplant (2008) 1.35
Reduced intensity conditioning for allogeneic hematopoietic cell transplantation: current perspectives. Biol Blood Marrow Transplant (2007) 1.31
Impact of in vivo T-cell depletion on outcome of AML patients in first CR given peripheral blood stem cells and reduced-intensity conditioning allo-SCT from a HLA-identical sibling donor: a report from the Acute Leukemia Working Party of the European Group for Blood and Marrow Transplantation. Bone Marrow Transplant (2014) 1.29
Thymic recovery after allogeneic hematopoietic cell transplantation with non-myeloablative conditioning is limited to patients younger than 60 years of age. Haematologica (2010) 1.19
Non-myeloablative conditioning with allogeneic hematopoietic cell transplantation for the treatment of high-risk acute lymphoblastic leukemia. Haematologica (2011) 1.17
What is the role for donor natural killer cells after nonmyeloablative conditioning? Biol Blood Marrow Transplant (2009) 1.16
Allogeneic hematopoietic cell transplantation: the state of the art. Expert Rev Hematol (2010) 1.16
Second solid cancers after allogeneic hematopoietic cell transplantation using reduced-intensity conditioning. Biol Blood Marrow Transplant (2014) 1.15
MHC class I-associated phosphopeptides are the targets of memory-like immunity in leukemia. Sci Transl Med (2013) 1.13
Mesenchymal stromal cells: a new tool against graft-versus-host disease? Biol Blood Marrow Transplant (2011) 1.11
Treatment of chronic graft-versus-host disease: Past, present and future. Korean J Hematol (2011) 1.11
Low-dose total body irradiation and fludarabine conditioning for HLA class I-mismatched donor stem cell transplantation and immunologic recovery in patients with hematologic malignancies: a multicenter trial. Biol Blood Marrow Transplant (2009) 0.97
Reduced-intensity conditioned allogeneic SCT in adults with AML. Bone Marrow Transplant (2015) 0.96
Factors governing the activation of adoptively transferred donor T cells infused after allogeneic bone marrow transplantation in the mouse. Blood (2007) 0.96
Allogeneic hematopoietic cell transplantation following minimal intensity conditioning: predicting acute graft-versus-host disease and graft-versus-tumor effects. Biol Blood Marrow Transplant (2013) 0.94
A multicentre UK study of GVHD following DLI: rates of GVHD are high but mortality from GVHD is infrequent. Bone Marrow Transplant (2014) 0.93
Comparison of reduced-intensity and myeloablative conditioning regimens for allogeneic hematopoietic stem cell transplantation in patients with acute myeloid leukemia and acute lymphoblastic leukemia: a meta-analysis. Stem Cells Dev (2014) 0.92
A randomized phase II trial of tacrolimus, mycophenolate mofetil and sirolimus after non-myeloablative unrelated donor transplantation. Haematologica (2014) 0.91
Anti-thymocyte globulin for conditioning in matched unrelated donor hematopoietic cell transplantation provides comparable outcomes to matched related donor recipients. Bone Marrow Transplant (2012) 0.90
Chronic Graft-versus-Host Disease--implementation of the National Institutes of Health Consensus Criteria for Clinical Trials. Biol Blood Marrow Transplant (2008) 0.89
Targeting the innate immune system as immunotherapy for acute myeloid leukemia. Front Oncol (2015) 0.89
Non-myeloablative allogeneic hematopoietic cell transplantation following fludarabine plus 2 Gy TBI or ATG plus 8 Gy TLI: a phase II randomized study from the Belgian Hematological Society. J Hematol Oncol (2015) 0.88
Donor chimerism early after reduced-intensity conditioning hematopoietic stem cell transplantation predicts relapse and survival. Biol Blood Marrow Transplant (2014) 0.85
Kinetics of IL-7 and IL-15 levels after allogeneic peripheral blood stem cell transplantation following nonmyeloablative conditioning. PLoS One (2013) 0.84
Extended mycophenolate mofetil and shortened cyclosporine failed to reduce graft-versus-host disease after unrelated hematopoietic cell transplantation with nonmyeloablative conditioning. Biol Blood Marrow Transplant (2007) 0.83
Nonmyeloablative unrelated donor hematopoietic cell transplantation to treat patients with poor-risk, relapsed, or refractory multiple myeloma. Biol Blood Marrow Transplant (2007) 0.83
BCR-ABL1 transcripts (MR(4.5)) at post-transplant 3 months as an early predictor for long-term outcomes in chronic myeloid leukemia. Korean J Intern Med (2016) 0.82
Graft-versus-leukemia effect of nonmyeloablative stem cell transplantation. Korean J Intern Med (2009) 0.81
Outcomes of human leukocyte antigen-matched sibling donor hematopoietic cell transplantation in chronic lymphocytic leukemia: myeloablative versus reduced-intensity conditioning regimens. Biol Blood Marrow Transplant (2014) 0.81
Treatment of hematological malignancies with nonmyeloablative, HLA-haploidentical bone marrow transplantation and high dose, post-transplantation cyclophosphamide. Best Pract Res Clin Haematol (2011) 0.81
Intracellular disposition of fludarabine triphosphate in human natural killer cells. Cancer Chemother Pharmacol (2008) 0.81
Current status of allogeneic transplantation for aggressive non-Hodgkin lymphoma. Curr Opin Oncol (2011) 0.81
Optimizing reduced-intensity conditioning regimens for myeloproliferative neoplasms. Expert Rev Hematol (2010) 0.78
Factors that contribute to long-term survival in patients with leukemia not in remission at allogeneic hematopoietic cell transplantation. J Exp Clin Cancer Res (2011) 0.78
The Effect of GVHD on Long-term Outcomes after Peripheral Blood Allogeneic Stem Cell Transplantation from an HLA-identical Sibling in Adult Acute Lymphocytic Leukemia: A Landmark Analysis Approach in Competing Risks. Int J Hematol Oncol Stem Cell Res (2014) 0.78
The uncertain role of unmodified mesenchymal stem cells in tumor progression: what master switch? Stem Cell Res Ther (2013) 0.78
Azacytidine mitigates experimental sclerodermic chronic graft-versus-host disease. J Hematol Oncol (2016) 0.77
Clinical endpoints in allogeneic hematopoietic stem cell transplantation studies: the cost of freedom. Biol Blood Marrow Transplant (2013) 0.76
A new approach for eradication of residual lymphoma cells by host nonreactive anti-third-party central memory CD8 T cells. Blood (2013) 0.76
Impact of irradiation and immunosuppressive agents on immune system homeostasis in rhesus macaques. Clin Exp Immunol (2015) 0.75
Strategies to reduce relapse after allogeneic hematopoietic cell transplantation in acute myeloid leukemia. Curr Hematol Malig Rep (2013) 0.75
Azacytidine prevents experimental xenogeneic graft-versus-host disease without abrogating graft-versus-leukemia effects. Oncoimmunology (2017) 0.75
A Review of Myeloablative vs Reduced Intensity/Non-Myeloablative Regimens in Allogeneic Hematopoietic Stem Cell Transplantations. Balkan Med J (2017) 0.75
National Institutes of Health consensus development project on criteria for clinical trials in chronic graft-versus-host disease: I. Diagnosis and staging working group report. Biol Blood Marrow Transplant (2005) 19.83
Hematopoietic cell transplantation (HCT)-specific comorbidity index: a new tool for risk assessment before allogeneic HCT. Blood (2005) 10.63
Reduced mortality after allogeneic hematopoietic-cell transplantation. N Engl J Med (2010) 7.20
HLA-haploidentical bone marrow transplantation for hematologic malignancies using nonmyeloablative conditioning and high-dose, posttransplantation cyclophosphamide. Biol Blood Marrow Transplant (2008) 7.10
Defining the intensity of conditioning regimens: working definitions. Biol Blood Marrow Transplant (2009) 6.22
Chronic graft-versus-host disease. Biol Blood Marrow Transplant (2003) 5.36
In Support of a Patient-Driven Initiative and Petition to Lower the High Price of Cancer Drugs. Mayo Clin Proc (2015) 4.70
A comparison of allografting with autografting for newly diagnosed myeloma. N Engl J Med (2007) 4.59
Measuring therapeutic response in chronic graft-versus-host disease: National Institutes of Health Consensus Development Project on Criteria for Clinical Trials in Chronic Graft-versus-Host Disease: IV. Response Criteria Working Group report. Biol Blood Marrow Transplant (2006) 4.09
Allogeneic hematopoietic cell transplantation for hematologic malignancy: relative risks and benefits of double umbilical cord blood. Blood (2010) 4.02
HLA-matched unrelated donor hematopoietic cell transplantation after nonmyeloablative conditioning for patients with hematologic malignancies. Blood (2003) 3.30
Graft-versus-host disease after nonmyeloablative versus conventional hematopoietic stem cell transplantation. Blood (2003) 3.16
Risk factors for acute GVHD and survival after hematopoietic cell transplantation. Blood (2011) 3.02
Five-year follow-up of patients with advanced chronic lymphocytic leukemia treated with allogeneic hematopoietic cell transplantation after nonmyeloablative conditioning. J Clin Oncol (2008) 2.99
CD20-specific adoptive immunotherapy for lymphoma using a chimeric antigen receptor with both CD28 and 4-1BB domains: pilot clinical trial results. Blood (2012) 2.97
Pathologic nodal evaluation improves prognostic accuracy in Merkel cell carcinoma: analysis of 5823 cases as the basis of the first consensus staging system. J Am Acad Dermatol (2010) 2.83
Duration of immunosuppressive treatment for chronic graft-versus-host disease. Blood (2004) 2.83
Autologous haemopoietic stem-cell transplantation followed by allogeneic or autologous haemopoietic stem-cell transplantation in patients with multiple myeloma (BMT CTN 0102): a phase 3 biological assignment trial. Lancet Oncol (2011) 2.78
Sustained AAV-mediated dystrophin expression in a canine model of Duchenne muscular dystrophy with a brief course of immunosuppression. Mol Ther (2007) 2.76
Comorbidity and disease status based risk stratification of outcomes among patients with acute myeloid leukemia or myelodysplasia receiving allogeneic hematopoietic cell transplantation. J Clin Oncol (2007) 2.66
Chronic GVHD risk score: a Center for International Blood and Marrow Transplant Research analysis. Blood (2011) 2.66
Recovery and long-term function after hematopoietic cell transplantation for leukemia or lymphoma. JAMA (2004) 2.65
Histopathologic diagnosis of chronic graft-versus-host disease: National Institutes of Health Consensus Development Project on Criteria for Clinical Trials in Chronic Graft-versus-Host Disease: II. Pathology Working Group Report. Biol Blood Marrow Transplant (2006) 2.63
The B-cell tumor-associated antigen ROR1 can be targeted with T cells modified to express a ROR1-specific chimeric antigen receptor. Blood (2010) 2.59
Solid cancers after allogeneic hematopoietic cell transplantation. Blood (2008) 2.56
Relapse risk in patients with malignant diseases given allogeneic hematopoietic cell transplantation after nonmyeloablative conditioning. Blood (2007) 2.49
Late cytomegalovirus disease and mortality in recipients of allogeneic hematopoietic stem cell transplants: importance of viral load and T-cell immunity. Blood (2002) 2.48
Ancillary therapy and supportive care of chronic graft-versus-host disease: national institutes of health consensus development project on criteria for clinical trials in chronic Graft-versus-host disease: V. Ancillary Therapy and Supportive Care Working Group Report. Biol Blood Marrow Transplant (2006) 2.44
Evaluation of NIH consensus criteria for classification of late acute and chronic GVHD. Blood (2009) 2.44
New treatment options have changed the survival of patients with follicular lymphoma. J Clin Oncol (2005) 2.40
Initial therapy of acute graft-versus-host disease with low-dose prednisone does not compromise patient outcomes. Blood (2008) 2.39
Phase II trial of CHOP chemotherapy followed by tositumomab/iodine I-131 tositumomab for previously untreated follicular non-Hodgkin's lymphoma: five-year follow-up of Southwest Oncology Group Protocol S9911. J Clin Oncol (2006) 2.38
Nonmyeloablative allogeneic hematopoietic cell transplantation in relapsed, refractory, and transformed indolent non-Hodgkin's lymphoma. J Clin Oncol (2007) 2.34
Allografting with nonmyeloablative conditioning following cytoreductive autografts for the treatment of patients with multiple myeloma. Blood (2003) 2.33
Increasingly frequent diagnosis of acute gastrointestinal graft-versus-host disease after allogeneic hematopoietic cell transplantation. Biol Blood Marrow Transplant (2004) 2.32
Long-term efficacy of sigmoidoscopy in the reduction of colorectal cancer incidence. J Natl Cancer Inst (2003) 2.29
Allogeneic hematopoietic cell transplantation after fludarabine and 2 Gy total body irradiation for relapsed and refractory mantle cell lymphoma. Blood (2004) 2.28
Global and organ-specific chronic graft-versus-host disease severity according to the 2005 NIH Consensus Criteria. Blood (2011) 2.26
National Institutes of Health Consensus Development Project on Criteria for Clinical Trials in Chronic Graft-versus-Host Disease: VI. Design of Clinical Trials Working Group report. Biol Blood Marrow Transplant (2006) 2.24
Significance of minimal residual disease before myeloablative allogeneic hematopoietic cell transplantation for AML in first and second complete remission. Blood (2013) 2.23
CMV reactivation after allogeneic HCT and relapse risk: evidence for early protection in acute myeloid leukemia. Blood (2013) 2.22